Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase One, Open Lab Study to Investigate the Impact of Rifampicin Administration on the PK of Dolutegravir When Dosed Once Daily at 50 or 100 mg in Healthy Volunteers

NCT03199690 is registered in ClinicalTrials.gov with St. Stephens Clinical Research as lead sponsor.

NCT NCT03199690
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03199690 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase One, Open Lab Study to Investigate the Impact of Rifampicin Administration on the PK of Dolutegravir When Dosed Once Daily at 50 or 100 mg in Healthy Volunteers
Lead sponsor
St. Stephens Clinical Research
Phase
Phase 1
Overall status
Unknown status
Start date
October 31, 2017
Completion date
March 31, 2018
Enrollment
16 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1-infection, tuberculosis